Inactivation of genes by CpG island methylation has emerged as a major mechanism in the etiology of adenocarcinoma of the lung in both smokers and never smokers. Our studies during the initial funding period for this grant revealed a higher prevalence for silencing of the O6-methylguanine-DNA methyltransferase gene in never smokers compared to smokers. Recent studies have demonstrated that the cytosine-DNA methyltransferases (DNMT) play a key role not only in de novo methylation of promoter regions, but also in the recruitment of deacetylated histones to establish heterochromatin over the gene promoter region that denies access to regulatory proteins needed for transcription. While our own studies have demonstrated an important role for DNMT1 in lung cancer development, the contribution of DNMT3a and 3b has not been clearly substantiated. Modification of cytosines and the histone code through methylation are both important factors in gene silencing; however, it is not clear which process initiates the cascade of events that culminate in transcriptional repression. The factors that both target genes for silencing and the trigger that allows either CpG methylation and/or histone modification to ensue are unknown. Our studies described within this application have led us to hypothesize that a decrease in gene transcription and the establishment of a """"""""methylation mark"""""""" within the gene promoter leads to gene silencing. This renewal will focus on the elucidation of gene targets and pathways involved in adenocarcinoma and define mechanisms involved in targeting, initiation, and propagation of gene-specific silencing through aberrant promoter hypermethylation. These goals will be accomplished through three specific aims.
Specific Aim 1 will identify the methylation profile in adenocarcinomas from smokers and never smokers for novel genes discovered through a microarray approach and known genes involved in controlling cell cycle, apoptosis, growth control/differentiation and invasion.
Specific Aim 2 will identify the role that the de novo cytosine-DNA methyltransferases 3a and 3b play in neoplastic transformation and gene-specific aberrant promoter hypermethylation. Human telomerase immortalized bronchial epithelial cells containing exogenous DNMT3a or 3b under the control of an inducible promoter will be exposed chronically to tobacco carcinogens. Finally, Specific Aim 3 will identify factors involved in establishing repressed chromatin around promoter regions for the p16 and death associated protein kinase genes. Transient transfection of minimized promoters into cell lines with an endogenously active or silenced gene will be used to elucidate the sequence of changes involved in repression of promoter activity. ? ? REVISED: July 7, 2005 ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project (R01)
Project #
5R01ES008801-07
Application #
7174694
Study Section
Cancer Etiology Study Section (CE)
Program Officer
Mastin, Patrick
Project Start
1998-02-05
Project End
2010-12-31
Budget Start
2007-02-23
Budget End
2008-01-31
Support Year
7
Fiscal Year
2007
Total Cost
$641,352
Indirect Cost
Name
Lovelace Biomedical & Environmental Research
Department
Type
DUNS #
045911138
City
Albuquerque
State
NM
Country
United States
Zip Code
87108
Belinsky, Steven A (2015) Unmasking the lung cancer epigenome. Annu Rev Physiol 77:453-74
Tessema, Mathewos; Yingling, Christin M; Liu, Yushi et al. (2014) Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers. Carcinogenesis 35:1248-57
Tessema, Mathewos; Yingling, Christin M; Snider, Amanda M et al. (2014) GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer. J Thorac Oncol 9:784-93
Tessema, M; Yingling, C M; Thomas, C L et al. (2012) SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. Oncogene 31:4107-16
Tessema, Mathewos; Yingling, Christin M; Grimes, Marcie J et al. (2012) Differential epigenetic regulation of TOX subfamily high mobility group box genes in lung and breast cancers. PLoS One 7:e34850
Leng, Shuguang; Bernauer, Amanda M; Hong, Chibo et al. (2011) The A/G allele of rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas. Clin Cancer Res 17:2014-23
Leng, Shuguang; Bernauer, Amanda M; Zhai, Rihong et al. (2011) Discovery of common SNPs in the miR-205/200 family-regulated epithelial to mesenchymal transition pathway and their association with risk for non-small cell lung cancer. Int J Mol Epidemiol Genet 2:145-55
Tellez, Carmen S; Juri, Daniel E; Do, Kieu et al. (2011) EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res 71:3087-97
Tessema, M; Klinge, D M; Yingling, C M et al. (2010) Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene 29:5159-70
Pulling, Leah C; Grimes, Marcie J; Damiani, Leah A et al. (2009) Dual promoter regulation of death-associated protein kinase gene leads to differentially silenced transcripts by methylation in cancer. Carcinogenesis 30:2023-30

Showing the most recent 10 out of 33 publications